Literature DB >> 43384

Plasma levels and beta-blocking effect of alpha-hydroxymetoprolol--metabolite of metoprolol--in the dog.

C G Regårdh, L Ek, K J Hoffmann.   

Abstract

The plasma levels and the beta-blocking effect of metoprolol and its active metabolite alpha-hydroxymetoprolol have been studied after i.v. bolus injections of the substances to dogs. For both substances the beta-blockade increased with the dose, and there was a linear relationship between percent reduction in exercise heart rate and the logarithm of plasma concentration. The dose of the metabolite, however, had to be 5 times higher than that of metoprolol to induce the same degree of beta-blockade. Because of differences in the volume of distribution, 2.0 liters/kg for alpha-OH-metoprolol and 3.5 liters/kg for metoprolol, the 5 times higher dose of alpha-OH-metoprolol resulted in 10 times higher plasma levels of the metabolite than of metoprolol. alpha-OH-Metoprolol was more slowly eliminated (t1/2 approximately 7.0 hr, total body clearance approximately 3.5 ml-kg-1-min-1) than metoprolol (t 1/2 approximately 2.0 hr, total body clearance approximately 20.0 ml-kg-1-min-1). Approximately 5% of an i.v. dose of metoprolol was metabolized to alpha-OH-metoprolol. The half-life of the endogenously formed metabolite was the same as after an i.v. dose of the compound.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 43384     DOI: 10.1007/bf01062389

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  5 in total

1.  Pharmacokinetic studies of metoprolol-(3-h) in the rat and the dog.

Authors:  K O Borg; E Fellenius; R Johansson; M Wallborg
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

2.  Metabolism of metoprolol-(3-h) in man, the dog and the rat.

Authors:  K O Borg; E Carlsson; K J Hoffmann; T E Jönsson; H Thorin; B Wallin
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

3.  The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites.

Authors:  K J Hoffmann; C G Regårdh; M Aurell; M Ervik; L Jordö
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

4.  Selected ion monitoring of metoprolol and two metabolites in plasma and urine using deuterated internal standards.

Authors:  M Ervik; K J Hoffmann; K Kylberg-Hanssen
Journal:  Biomed Mass Spectrom       Date:  1981-07

5.  Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function.

Authors:  L Jordö; P O Attman; M Aurell; L Johansson; G Johnsson; C G Regårdh
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

  5 in total
  13 in total

1.  Soft Drugs VI. The Application of the Inactive Metabolite Approach for Design of Soft β-Blockers1?2.

Authors:  N Bodor; Y Oshiro; T Loftsson; M Katovich; W Caldwell
Journal:  Pharm Res       Date:  1984-05       Impact factor: 4.200

2.  The relationship between serum concentrations and central nervous system actions of metoprolol.

Authors:  F M Gengo; J C Ermer; C Carey; G C Kalonaros; W B McHugh
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-02       Impact factor: 10.154

Review 3.  The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

Review 4.  Oxidation phenotype and the metabolism and action of beta-blockers.

Authors:  M S Lennard
Journal:  Klin Wochenschr       Date:  1985-04-01

5.  The effect of hydralazine on steady-state plasma concentrations of metoprolol in pregnant hypertensive women.

Authors:  S Lindeberg; B Holm; P Lundborg; C G Regårdh; B Sandström
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  Pharmacokinetics of metoprolol during pregnancy and lactation.

Authors:  Rachel J Ryu; Sara Eyal; Thomas R Easterling; Steve N Caritis; Raman Venkataraman; Gary Hankins; Erik Rytting; Kenneth Thummel; Edward J Kelly; Linda Risler; Brian Phillips; Matthew T Honaker; Danny D Shen; Mary F Hebert
Journal:  J Clin Pharmacol       Date:  2015-12-04       Impact factor: 3.126

7.  Pharmacokinetics of metoprolol in healthy, elderly, non-smoking individuals after a single dose and two weeks of treatment.

Authors:  M Larsson; S Landahl; P Lundborg; C G Regårdh
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

8.  Pharmacokinetics of metoprolol and its metabolite alpha-OH-metoprolol in healthy, non-smoking, elderly individuals.

Authors:  C G Regårdh; S Landahl; M Larsson; P Lundborg; B Steen; K J Hoffmann; P O Lagerström
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  Pharmacokinetics of metoprolol in patients with hepatic cirrhosis.

Authors:  C G Regårdh; L Jordö; M Ervik; P Lundborg; R Olsson; O Rönn
Journal:  Clin Pharmacokinet       Date:  1981 Sep-Oct       Impact factor: 6.447

Review 10.  Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease.

Authors:  G L Plosker; S P Clissold
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.